Matao

Researchers are investigating the effect of low dose colchicine, an anti-inflammatory drug, on reducing vascular events in patients with symptomatic peripheral artery disease (PAD). This Phase 3 randomized, double-blind, multicenter trial involves 6,150 participants and aims to prevent major cardiovascular and limb complications such as heart attacks, strokes, cardiovascular deaths, acute limb ischemia, and vascular amputations. The study focuses on patients who have PAD with various levels of severity and associated vascular risks. Participants are randomly assigned to receive either a daily 0.5 mg colchicine tablet or a matching placebo. Both the active drug and placebo look the same to ensure that patients, investigators, and study staff remain unaware of the treatment assignments. The trial includes an active run-in period before randomization. The colchicine is administered orally each day, and the trial medication is securely stored according to specific guidelines. During the study, patients will be monitored for major adverse cardiovascular and limb events over 3 to 5 years. These events include cardiovascular death, heart attacks, strokes, severe limb ischemia requiring vascular intervention, or major amputation. Researchers will assess cardiovascular health and limb status regularly, tracking serious events to evaluate the drug's impact. Safety and adherence to treatment will be closely followed throughout the study period.